Atorvastatin
Stroke Disorder
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Duan Chuanzhi
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06052020CT.gov Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study | — | Unknown | — | — | — |
NCT05839236CT.gov COVID-19 Vaccination Detoxification in LDL-C | — | Unknown | — | — | — |
NCT03635749CT.gov Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis | — | Unknown | — | — | — |
NCT02850081CT.gov Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes | — | Terminated | — | — | — |
NCT02458755CT.gov Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis | — | Unknown | — | — | — |
NCT01518231CT.gov Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke | — | Unknown | — | — | — |
NCT01073800CT.gov Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill | — | Completed | — | — | — |
NCT00805311CT.gov Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis | — | Terminated | — | — | — |
NCT00636766CT.gov Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque | — | Completed | — | — | — |
NCT00079638CT.gov Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atorvastatin (this asset) | Duan Chuanzhi | Approved | BB · 71 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Atorvastatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P4 | A · 83 |
| Hyperlipidemia | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Atorvastatin in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/atorvastatin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →